Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands	Sep. 30, 2011	Dec. 31, 2010
Current Assets:
Cash and cash equivalents	$ 110,293	$ 53,557
Marketable securities	38,604	42,117
Accounts receivable, net of allowance for doubtful accounts of $430 and $339, respectively	47,766	21,051
Inventories, net	10,285	4,234
Prepaid expenses and other current assets	571	906
Total current assets	207,519	121,865
Investments	11,880	8,569
Property and equipment, net	2,821	3,158
Intangible assets, net	43,078	29,605
Other assets	576	434
TOTAL ASSETS	265,874	163,631
Current Liabilities:
Accounts payable and other accrued obligations	50,054	38,704
Accrued compensation and related expenses	3,638	3,313
Deferred revenue	12,300	12,300
Common stock warrant liability	0	3,904
Accrued drug development costs	9,561	5,101
Total current liabilities	75,553	63,322
Capital lease obligations	17	40
Deferred revenue and other credits--less current portion	16,173	25,495
Zevalin related contingent obligations	298	298
Total liabilities	92,041	89,155
Commitments and contingencies
Preferred stock, $0.001 par value; 5,000,000 shares authorized:
Common stock, $0.001 par value--175,000,000 shares authorized; 57,403,724 and 51,459,284 issued and outstanding at September 30, 2011 and December 31, 2010, respectively	57	51
Additional paid-in capital	446,804	384,757
Accumulated other comprehensive loss	(147)	(92)
Accumulated deficit	(270,164)	(310,400)
Less: Treasury stock at cost; 353,055 shares at September 30, 2011	(2,840)	0
Total stockholders' equity	173,833	74,476
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	265,874	163,631
Series B junior participating preferred stock
Preferred stock, $0.001 par value; 5,000,000 shares authorized:
Preferred stock value
Series E convertible preferred stock
Preferred stock, $0.001 par value; 5,000,000 shares authorized:
Preferred stock value	$ 123	$ 160